Medibio Announces ISO 13485 Certification
SYDNEY, Australia and MINNEAPOLIS, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company ) (ASX:MEB) (OTCQB:MDBIF) has received a Certificate of Compliance certifying that the Company's Quality Management System complies with the requirements of ISO 13485. This also includes conformance with the Canadian Medical Device Conformity Assessment System (CMDCAS).
The certification was issued by DQS Med, the Notified Body appointed to assess Medibio's submission for CE Mark. It signifies that Medibio has established a comprehensive quality system for the design and manufacturing of medical devices. ISO 13485 is recognized internationally as a universal measure of quality and is a critical prerequisite to securing CE Mark and other regulatory certifications.
"This is an major milestone for the Company," said Medibio's CEO & Managing Director, Mr. Jack Cosentino. "This accomplishment reflects the work of all individuals within the organization who all believe that this achievement of ISO certification echoes Medibio's commitment to the highest level of quality management and to operational and production excellence."
Following receipt of ISO certification, Medibio reaffirms its expectation of gaining CE Mark shortly.
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
Further Information: Website: www.medibio.com.au
Medibio Shareholder Enquiries:
T: +1 (952) 222-0551
Australian Media Enquiries:
T: +61 (0) 412 036 231
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Erytech Pharma S.A.18.1.2019 07:01 | Pressemeddelelse
ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting
Taconic Biosciences17.1.2019 15:31 | Pressemeddelelse
Taconic Biosciences’ Animals Complete Most Recent Mission to the International Space Station
MPP Global17.1.2019 12:31 | Pressemeddelelse
MPP Global Bridges the Innovation Gap by Centralising Physical and Digital Subscriber Management and Billing in a Single Cloud Platform
ADC Therapeutics SA16.1.2019 07:01 | Pressemeddelelse
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
CGAP15.1.2019 14:10 | Pressemeddelelse
Credit Suisse Partners with CGAP on Digital Finance to Catalyze Delivery of Energy, Water and other Services to Low Income People
TrueCommerce15.1.2019 14:01 | Pressemeddelelse
TrueCommerce Recognized as a Leader in IDC MarketScape for Worldwide Multi-Enterprise Supply Chain Commerce Network
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum